|Bid||0.3780 x 1300|
|Ask||0.4300 x 2900|
|Day's Range||0.3250 - 0.4100|
|52 Week Range||0.3000 - 1.8400|
|Beta (3Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Every investor in Applied DNA Sciences, Inc. (NASDAQ:APDN) should be aware of the most powerful shareholder groups...
Applied DNA Sciences Inc. (APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the signing of a five-year Agreement with Germany-based Montblanc-Simplo GMBH (“Montblanc”) for the provision of unique SigNature® DNA marks for individual Montblanc clients. This Agreement culminates a rigorous 18-month product development and qualification program between Applied DNA and Montblanc for SigNature DNA with Beacon® in a range of specialist inks for use in the high-end range of Montblanc writing instruments.
LineaRx, Inc., a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ:APDN), announced today that it has received multiple purchase orders, from several major developers of gene and cell therapies, for its proprietary and patented large-scale, polymerase-chain-reaction (PCR)-produced linear DNA. LineaRx believes this momentum reflects increasing interest across the biotech industry to pursue a cleaner, higher-performing alternative to plasmid DNAs that are produced by fermentation in bacteria. Under these Phase 1 CRO (Contract Research Organization) agreements, the performance of linear DNA will be benchmarked by criteria such as gene expression, and cell viability, against existing data from DNA produced using plasmids.
LineaRx, Inc. a wholly-owned subsidiary of Applied DNA Sciences, Inc. (APDN), announced today that it has shipped multiple customized linear DNA amplicons to Evotec SE, a well-known therapeutic development company, to support their research efforts related to neurodegenerative diseases such as Huntington’s, Parkinson’s or Alzheimer’s disease. “Evotec SE, like a growing number of other cutting-edge biotech companies, sees value in evaluating linear DNA as a foundation for their research and recognizes the strengths of LineaRx in the design and large-scale production of linear DNA using LineaRx’s proprietary platform for DNA production by polymerase chain reaction (“PCR”).
ETCH biotrace to Combine Applied DNA’s DNA tag-based Forensic Traceability and Authenticity with TruTrace's Industry Blockchain Hub to Deliver Unparalleled Tag-Test-Track Capabilit
Applied DNA Sciences, Inc. (APDN), announced today that its scientific paper entitled, ‘Rapid authentication of pharmaceuticals via DNA tagging and field detection’, has been published in the June 2019 edition of PLOS ONE, detailing a novel Physical-Chemical Identifier (PCID) to authenticate and track legitimate pharmaceutical products through the pharmaceutical supply chain.
Includes Implementation of TheraCann’s ETCH biotrace™ platform Utilizing Technology from Applied DNA
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the “Company”), provides an update today on its accomplishments toward commercial-scale production to support global material traceability for companies declaring sustainability goals to be achieved by 2020. CertainT-verifiable products are now available through supply chain partners and brands, including Amazon and other e-commerce and retail stores, with outlook for growth as product flows to store shelves. The CertainT platform and forensic services were conceived to empower companies with the most advanced commercially-scalable and affordable technologies to help prove their compliance with stated sustainability goals.
Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), today announced that it has closed the loop on traceability for Egyptian Pima using DNA-based genotyping assays for cotton authentication. The Egyptian Pima developments join and expand a series of US Pima cotton assays performed within Applied DNA testing services and are based on work conducted over the past 3 years related to the validation of a known library of cotton cultivar standards.
LineaRx, a wholly-owned subsidiary of Applied DNA Sciences, Inc. (APDN), announced that it is in process of designing new, custom amplicons for an existing customer in the in vitro diagnostics market. The diagnostic assay is expected to be available and qualified in 2020, potentially resulting in increasing revenue from an existing supply agreement. The company currently receives annual orders for large-scale DNA from this customer under a 5-year supply agreement executed in 2017.
Applied DNA Sciences, Inc. (APDN), announced today that partner TheraCann International Benchmark Corporation (“TheraCann”), a leading full service international cannabis consultancy and technology firm, in conjunction CannAcubed Pte Ltd (CannAcubed), a pioneer in the China cannabis space with a focus on building the world’s largest diversified cannabis operations, has formed an agreement focused on the implementation of TheraCann’s molecular-tagging ETCH biotrace™ technology for the industrial hemp and cannabinoid markets in China.
Applied DNA Sciences, Inc. (APDN), will hold its 2019 Annual Meeting of Stockholders on Thursday, May 16, 2019. On that date, the company will provide an audio-only live webcast of the meeting beginning at 10:00 AM ET. Slide presentations accompanying the webcast will be available for download at that time on the ‘Events and Presentations’ portion of the ‘Investors’ page to the company’s website.
The Stony Brook, New York-based company said it had a loss of 8 cents per share. The DNA-based security technology company posted revenue of $778,500 in the period. Its adjusted revenue was $778,000. In ...
Applied DNA Sciences, Inc. (APDN), announced today that American & Efird (A&E), a portfolio company of Elevate Textiles and the world’s foremost manufacturer and distributor of industrial and consumer sewing thread, embroidery thread and technical textiles, has announced it will be previewing its new line of advanced identification threads, branded “Integrity” later this month. A&E will publicly display this latest breakthrough at the upcoming Texprocess trade show in Frankfurt Germany.
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”), a leader in PCR-based manufacturing for product authenticity and traceability solutions, announced today it received an order for the implementation of its SigNature® T cotton traceability system in Egypt to indelibly mark two varietals of high-value Egyptian cotton, widely acknowledged to be among the finest in the world. The molecular tag and delivery system have been shipped and cotton tagging is expected to commence within the month.
Applied DNA Sciences, Inc. (APDN), announced today it plans to release financial results for its fiscal 2019 second quarter ended March 31, 2019 after market close on Thursday, May 9, 2019. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the Internet.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While it may not be enough for some shareholders, we think it is good to see the Applied DNA Scien...
LineaRx, Inc. ( the “Company”) a wholly owned subsidiary of Applied DNA Sciences, Inc. (APDN), announced today that it has improved expression levels and survival rates of linear DNA constructs delivered without viruses or plasmids to human T cells. In collaboration with Avectas, a cell engineering technology business enabling the manufacture of cell therapies, LineaRx has achieved a greater than four-fold increase in cell survival, and a more than 50% increase in linear gene expression of a model amplicon.
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has received the first $1 million of a $5 million licensing fee as per the terms of its exclusive agreement entered into with TheraCann International Corporation (“TheraCann”) on March 29, 2019. “The agreement with TheraCann represents further validation of the commercialization of our CertainT® technology platform across industries where compliance, control and tracking are essential to marketplace safety and security,” noted Dr. James A. Hayward, president and CEO of Applied DNA. “Powered by our CertainT platform, TheraCann’s ETCH biotraceTM system can provide the global legal cannabis and hemp industries the unparalleled ability to ensure true authentication and origin verification for products through the supply chain.
CertainT Verified Recycled PET Bedding Drives Sustainability for Global E-commerce
Applied DNA Sciences Inc. (APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the signing of a non-binding Memorandum of Understanding (“MOU”) with Netherlands-based Stahl, the world leader in process chemicals for leather products, performance coatings and other substrates. The MOU is expected to be followed by a definitive agreement. Under the terms of the MOU, the parties will continue the evaluation of molecular tagging of process chemicals and coatings utilizing Stahl’s product offerings as a point of entry into supply chains for the Company’s molecular tags.
Applied DNA Sciences, Inc. (APDN) announced today that LineaRx, (the “Company”), its subsidiary focused on next-generation biotherapeutics, has achieved anti-CD-19 CAR (Chimeric Antigen Receptor) expression in human T Cells via its proprietary, non-viral, plasmid-free (NVPF) manufacturing platform. To the Company’s knowledge, this seminal event represents the first time that a human T cell has been shown to express an anti-CD19 CAR from a gene construct utilizing linear DNA produced via a scalable PCR (Polymerase Chain Reaction) manufacturing process. The Company views this development as an important option for all gene therapies that currently use virus-delivery platforms, but especially for immune-oncology therapies that use virus delivery of synthetic genes to redirect a patient’s T cells, known as CAR therapy.